Abstract
Postoperative complications following cancer surgeries are still hard to predict despite the historical efforts towards the creation of standard clinical risk scores. The differences among score calculators, contribute for the creation of highly specialized tools, with poor reusability in foreign contexts, resulting in larger prediction errors in clinical practice.
This work aims to predict postoperative complications risk for cancer patients, offering two major contributions. First, to develop and evaluate a machine learning-based risk score, specific for the Portuguese population using a retrospective cohort of 847 cancer patients undergoing surgery between 2016 and 2018, predicting 4 outcomes of interest: i) existence of postoperative complications, ii) severity level of complications, iii) number of days in the Intermediate Care Unit (ICU), and iv) postoperative mortality within 1 year. An additional cohort of 137 cancer patients was used to validate the models. Second, to support the study with relevant findings and improve the interpretability of predictive models.
In order to achieve these objectives, a robust methodology for the learning of risk predictors is proposed, offering new perspectives and insights into the clinical decision process. For postoperative complications the mean Receiver Operating Characteristic Curve (AUC) was 0.69, for complications’ severity mean AUC was 0.65, for the days in the ICU the Mean Absolute Error (MAE) was 1.07 days, and for one-year postoperative mortality the mean AUC was 0.74, calculated on the development cohort.
In this study, risk predictive models which may help guide physicians at estimating cancer patient’s risk of developing surgical complications were developed. Additionally, a web-based decision support system is further provided to this end.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by the FCT, through IDMEC, under LAETA project (UIDB/50022/2020), IPOscore project with reference DSAIPA/DS/0042/2018, and Data2Help (DSAIPA/DS/0044/2018). This work was further supported by the LAQV, financed by national funds from FCT/MCTES (UIDB/50006/2020) and the contract CEECIND/01399/2017.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IPO-Porto Ethics Committee approved (CES IPO:91/019) the analysis of the anonymized data.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data may be available upon a written request addressed to the authors.
https://github.com/danielmg97/cancer-prognostication-iposcore